NEWS & MEDIA
ivWatch Inks Distribution Deal with Terumo
September 29, 2017
ivWatch has recently signed a licensing and distribution agreement with Terumo to improve patient safety, according to a Sept. 21 press release. Terumo will become the exclusive distributor of the ivWatch Model 400 and ivWatch OEM board in Japan. ivWatch technology can be integrated with other patient monitoring systems, infusion pumps and other devices easily with the ivWatch OEM board. The agreement also allows Terumo to exclusively integrate ivWatch into existing and future Terumo products in Japan.
Read the full article here.
Gary Warren, ivWatch President & CEO, will join the Review Committee of the Atlantic Pediatric Device Consortium (APDC) Pediatric Device Innovation Competition. The Pediatric Device Innovation Competition is a seed grant competition that provides an opportunity for the scientific and business community including entrepreneurs, clinicians, scientists, businesses, academic researchers and medical and engineering graduate and undergraduate students, to develop and commercialize a pediatric medical device. Grants are expected to range from $5,000 to a maximum of $50,000 for one year.
Mr. Warren has extensive executive experience in developing and managing high-growth technology and venture-backed private companies with a focus on product management and delivery in small start-up companies, large public companies, and government programs. For the past seven years, Mr. Warren has been with ivWatch , the market leader in developing, commercializing and distributing non-invasive sensor technology to monitor a patient’s IV site for complications. The company’s flagship product, the ivWatch Model 400, is an FDA-cleared stand-alone continuous monitoring system that allows clinicians to manage the risk of IVs by providing early detection of infiltration and extravasation. Reliable early detection of infiltrations and extravasations, when fluid leaks outside of the vein, is necessary to help hospitals manage the risks associated with this common invasive procedure.
The APDC is an FDA funded consortium based out of Georgia Tech, Emory University, Children’s Healthcare of Atlanta, and Virginia Commonwealth University that provides a national platform to translate medical device ideas from concept to commercialization. APDC’S mission is to enhance the lives of children through the development of novel pediatric medical devices, which are both safe and effective. The consortium provides an environment of creativity, where ideas are reviewed, tested, and developed.
As part of the review committee, Mr. Warren will assess the proposals on a number of factors including: 1) clinical significance of the pediatric device, 2) approach to product development, 3) likelihood for marketing success, 4) project team, environment, and resources, and 5) potential for additional funding. Project presentations take place today, Monday, September 25, 2017 on the Virginia Commonwealth University (VCU) campus with notification of awards announced on October 30, 2017.
The Atlantic Pediatric Device Consortium (APDC) is one of seven FDA funded pediatric device consortia awarded in 2013. A collaboration between Georgia Tech, Emory University, Children’s Healthcare of Atlanta and Virginia Commonwealth University, APDC provides a national platform to translate ideas through its product development pathway all the way to commercialization. The mission of APDC is to enhance the lives of children through the development of novel pediatric medical devices, which are both safe and effective. Since 2011 the Consortium has created an environment of creativity, where innovative ideas are reviewed, tested and developed and it reflects the long term commitment of our partner institutions. Success is measured by the development, production and marketing of several novel pediatric medical devices.
ivWatch, LLC is a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. ivWatch provides a first-of-its-kind, FDA-cleared, noninvasive medical device that continuously monitors peripheral IVs for infiltration and extravasation events. The ivWatch Model 400 aims to help eliminate patient harm associated with adverse events and to reduce drug delivery errors. The ivWatch OEM Board integrates ivWatch technology into existing products, enabling OEMs to help healthcare providers deliver a higher level of patient care and to reduce risks related to IV therapy.
The ivWatch OEM Board is not an FDA-cleared device. It is the responsibility of the Original Equipment Manufacturer integrating ivWatch technology to secure the proper regulatory clearance. Follow us on Twitter@ivWatch or Facebook @ivWatchLLC.
MEDIA CONTACT: Leah Moore, email@example.com, Office (855) 489-2824 x7031, Mobile (757) 839-5653
ivWatch company and product information is available. If you would like more information, please contact us at firstname.lastname@example.org with your request.
Press kit: Download
ivWatch Monitored PIV Infographic: Download
ivWatch Patient Safety Infographic: Download
ivWatch Company Brochure: Download
ivWatch Pediatric Brochure: Download
ivWatch OR/Anesthesia Brochure: Download
ivWatch Oncology Brochure: Download
ivWatch ICU Brochure: Download
Model 400 Fact Sheet: Download
Model 400 Product Manual: Download
OEM Tech Sheet: Download
For media inquiries, please contact:
ivWatch Director, Marketing
855-489-2824 ext. 7031